Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)

Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
State: District of Columbia
Type of Government: Federal
FSC Category:
  • A - Research and development
NAICS Category:
  • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Set Aside: No Set aside used
Posted Date: Oct 17, 2025
Due Date: Dec 19, 2025
Solicitation No: ARPA-H-SOL-25-122
Original Source: Please Login to View Page
Contact information: Please Login to View Page
Bid Documents: Please Login to View Page

Description

Follow
Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Active
Contract Opportunity
Notice ID
ARPA-H-SOL-25-122
Related Notice
ARPA-H-SN-25-131
Department/Ind. Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
NATIONAL INSTITUTES OF HEALTH
Office
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)
Looking for contract opportunity help?

APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.

APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.

The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).

General Information View Changes
  • Contract Opportunity Type: Solicitation (Updated)
  • Updated Published Date: Oct 17, 2025 03:49 pm EDT
  • Original Published Date: Sep 25, 2025 09:15 am EDT
  • Updated Date Offers Due: Dec 19, 2025 11:59 pm EST
  • Original Date Offers Due: Dec 19, 2025 11:59 pm EST
  • Inactive Policy: 15 days after date offers due
  • Updated Inactive Date: Jan 03, 2026
  • Original Inactive Date: Jan 03, 2026
  • Initiative:
    • None
Classification
  • Original Set Aside: No Set aside used
  • Product Service Code: AN13 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT
  • NAICS Code:
    • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
  • Place of Performance:
    Washington , DC 20005
    USA
Description View Changes

Amendment 2: Changes to the ISO



The purpose of this amendment is to amend the THRIVE ISO. An updated version of the ISO and an updated version of the ISO with tracked changes are included as attachments. Changes to the ISO include:




  1. Cost share is now strongly encouraged instead of mandatory.

  2. Multi-party teaming arrangements are no longer required.

  3. ARPA-H's involvement with regulatory facilitation has been clarified.



Please review the amended ISO for all changes.



----------------------------------------------------------------------------------------------------------------



Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments.



----------------------------------------------------------------------------------------------------------------



The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease.



Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122.

For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131.



Solution summaries are due October 31, 2025, 11:59 PM ET.



For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive




Attachments/Links
Contact Information View Changes
Contracting Office Address
  • 1301 K Street NW Suite 1200 West
  • Washington , DC 20005
  • USA
Primary Point of Contact
Secondary Point of Contact


History

Related Document

Sep 25, 2025[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Oct 9, 2025[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Oct 27, 2025[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Nov 15, 2025[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Dec 2, 2025[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Dec 15, 2025[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Jan 9, 2026[Solicitation (Updated)] Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Get Government Bids Like This by Email Receive daily bid alerts that match your keywords, business categories, and target regions.
View Sample Report Start Free Trial

See Also

Research Initiatives in Suppo...

Follow Research Initiatives in Support of FHWA Next Generation Structural Materials and Systems

TRANSPORTATION, DEPARTMENT OF

Due by 4/01/2029

Federal Bureau of Investigati...

Follow Federal Bureau of Investigation (FBI) - Office of Chief Information Officer (OCIO)

JUSTICE, DEPARTMENT OF

Due by 5/16/2027

FTA Broad Agency Announcement...

Follow FTA Broad Agency Announcement (FY26) -- "Research Initiatives in Support of Safety,

TRANSPORTATION, DEPARTMENT OF

Due by 10/19/2026

Establishing a Roster of Pre-...

Solicitation # Details Opening Date Closing Date Other Documents DCSC-26-RFPQ-1 Establishing a Roster

District of Columbia Courts

Due by 9/30/2026

* Disclaimer: This website provides information about bids, requests for proposals (RFPs), or requests for qualifications (RFQs) for convenience only and does not serve as an official public notice. Individuals who wish to respond to or inquire about bids, RFPs, or RFQs should contact the relevant government department directly.